Click on headlines below to download research

MSRD agreement early validation for IRL757
IRLAB Therapeutics | 08/05/2024

The McQuade Center for Strategic Research and Development (MSRD) has signed an exclusive R&D collaboration for Irlab’s pre-clinical candidate IRL757,…

...read more

Beyond PD-LID, a closer look at PD-psychosis
IRLAB Therapeutics | 08/04/2024

While IRLAB Therapeutics’ immediate focus is on advancing mesdopetam in levodopa-induced dyskinesia (PD-LID) following the recent green light from…

...read more

FDA thumbs up to mesdopetam’s Phase III plan
IRLAB Therapeutics | 25/03/2024

IRLAB Therapeutics has confirmed the FDA’s alignment with its proposed Phase III programme for mesdopetam in levodopa-induced dyskinesias (PD-LIDs),…

...read more